Fedratinib Dosing for CYP2C19 and CYP3A4 Inhibitor Interactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for myeloproliferative disorders, such as myelofibrosis, face challenges when administered concurrently with dual CYP2C19 and CYP3A4 inhibitors due to potential drug-drug interactions, leading to safety and tolerability issues.
Innovation Solution
Administering a compound of formula (I), or its pharmaceutically acceptable salt and solvate, at adjusted doses while monitoring patients for adverse reactions, and potentially co-administering thiamine or 5-HT3 receptor antagonists to manage side effects and improve tolerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fedratinib is administered at standard dose to patients concurrently receiving dual CYP2C19 and CYP3A4 inhibitors, then therapeutic efficacy is maintained, but safety and tolerability deteriorate due to drug-drug interactions
Solution Approach 1:
The patent applies parameter changes by adjusting the dose of fedratinib from the standard dose to a reduced dose when co-administered with dual CYP2C19 and CYP3A4 inhibitors. This dosage modification resolves the technical contradiction by maintaining therapeutic efficacy while reducing adverse reactions and toxicity associated with drug-drug interactions.
2Productivity
If fedratinib is administered to patients with complex pharmacokinetic profile, then treatment of myeloproliferative disorders is achieved, but drug interactions with CYP inhibitors cause safety issues
Solution Approach 1:
The patent applies preliminary action by providing dosing recommendations before co-administration of fedratinib with dual CYP2C19 and CYP3A4 inhibitors. The prescribing information advises patients to avoid taking fedratinib with dual CYP inhibitors, or to use alternative CYP inhibitor regimens, thereby preventing safety issues before they occur.
Solution Approach 2:
The patent modifies the dosage parameter of fedratinib when co-administered with dual CYP inhibitors, reducing the dose to maintain safety while preserving treatment effectiveness for myeloproliferative disorders.
3Adaptability or versatility
If dual CYP2C19 and CYP3A4 inhibitors are co-administered with fedratinib, then comprehensive treatment coverage is achieved, but adverse reactions increase
Solution Approach 1:
The patent resolves this contradiction by changing the dosage parameter of fedratinib when co-administered with dual CYP inhibitors. The reduced dosage maintains treatment flexibility and comprehensive coverage while minimizing toxicity and adverse reactions.
Data Source
AI summary
The present disclosure provides methods of treating myeloproliferative disorders in patients concurrently receiving a dual CYP2C19 and CYP3A4 inhibitor.